PT Darya-Varia Laboratoria Tbk (DVLA.JK)
IDR 1505.0
(1.01%)
IDR 1505.0
(1.01%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 762.07 Billion IDR | -51.45% |
| 2022 | 1569.72 Billion IDR | 94.81% |
| 2021 | 805.78 Billion IDR | 10.69% |
| 2020 | 727.97 Billion IDR | 7.05% |
| 2019 | 680.05 Billion IDR | 0.38% |
| 2018 | 677.46 Billion IDR | -0.91% |
| 2017 | 683.71 Billion IDR | 14.64% |
| 2016 | 596.38 Billion IDR | 7.28% |
| 2015 | 555.91 Billion IDR | 13.28% |
| 2014 | 490.74 Billion IDR | -0.57% |
| 2013 | 493.57 Billion IDR | 8.49% |
| 2012 | 454.94 Billion IDR | -1.76% |
| 2011 | 463.1 Billion IDR | 2.78% |
| 2010 | 450.55 Billion IDR | 8.11% |
| 2009 | 416.74 Billion IDR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 197.36 Billion IDR | 3.42% |
| 2024 Q3 | 234.46 Billion IDR | 3.25% |
| 2024 Q2 | 225.54 Billion IDR | 14.28% |
| 2023 Q4 | 190.83 Billion IDR | -1.38% |
| 2023 FY | 762.07 Billion IDR | -51.45% |
| 2023 Q1 | 190.56 Billion IDR | -79.88% |
| 2023 Q2 | 208.94 Billion IDR | 9.65% |
| 2023 Q3 | 193.49 Billion IDR | -7.4% |
| 2022 Q4 | 946.95 Billion IDR | 292.9% |
| 2022 Q1 | 182.85 Billion IDR | -34.61% |
| 2022 Q2 | 198.29 Billion IDR | 8.44% |
| 2022 FY | 1569.72 Billion IDR | 94.81% |
| 2022 Q3 | 241.02 Billion IDR | 21.55% |
| 2021 Q4 | 279.63 Billion IDR | 59.29% |
| 2021 FY | 805.78 Billion IDR | 10.69% |
| 2021 Q1 | 166.37 Billion IDR | -29.36% |
| 2021 Q2 | 184.23 Billion IDR | 10.73% |
| 2021 Q3 | 175.54 Billion IDR | -4.71% |
| 2020 Q1 | 189.56 Billion IDR | 27.69% |
| 2020 Q4 | 235.51 Billion IDR | 42.65% |
| 2020 Q3 | 165.09 Billion IDR | 19.8% |
| 2020 FY | 727.97 Billion IDR | 7.05% |
| 2020 Q2 | 137.8 Billion IDR | -27.3% |
| 2019 Q3 | 181.74 Billion IDR | -2.95% |
| 2019 Q1 | 162.57 Billion IDR | -17.07% |
| 2019 Q2 | 187.27 Billion IDR | 15.19% |
| 2019 FY | 680.05 Billion IDR | 0.38% |
| 2019 Q4 | 148.45 Billion IDR | -18.31% |
| 2018 FY | 677.46 Billion IDR | -0.91% |
| 2018 Q4 | 196.03 Billion IDR | 26.08% |
| 2018 Q3 | 155.47 Billion IDR | 5.41% |
| 2018 Q2 | 147.5 Billion IDR | -17.34% |
| 2018 Q1 | 178.44 Billion IDR | -13.89% |
| 2017 Q2 | 171.69 Billion IDR | 21.87% |
| 2017 Q3 | 163.9 Billion IDR | -4.54% |
| 2017 Q1 | 140.87 Billion IDR | -17.98% |
| 2017 FY | 683.71 Billion IDR | 14.64% |
| 2017 Q4 | 207.23 Billion IDR | 26.44% |
| 2016 Q2 | 157.87 Billion IDR | 17.87% |
| 2016 Q4 | 171.76 Billion IDR | 29.33% |
| 2016 FY | 596.38 Billion IDR | 7.28% |
| 2016 Q1 | 133.94 Billion IDR | -20.42% |
| 2016 Q3 | 132.8 Billion IDR | -15.88% |
| 2015 Q3 | 140.51 Billion IDR | 1.25% |
| 2015 FY | 555.91 Billion IDR | 13.28% |
| 2015 Q1 | 108.3 Billion IDR | -24.98% |
| 2015 Q2 | 138.78 Billion IDR | 28.15% |
| 2015 Q4 | 168.3 Billion IDR | 19.78% |
| 2014 Q1 | 136.38 Billion IDR | 38.7% |
| 2014 FY | 490.74 Billion IDR | -0.57% |
| 2014 Q4 | 144.35 Billion IDR | 1.82% |
| 2014 Q3 | 141.77 Billion IDR | 107.8% |
| 2014 Q2 | 68.22 Billion IDR | -49.97% |
| 2013 Q3 | 123.18 Billion IDR | -18.11% |
| 2013 Q1 | 120.9 Billion IDR | 4.14% |
| 2013 FY | 493.57 Billion IDR | 8.49% |
| 2013 Q4 | 98.33 Billion IDR | -20.18% |
| 2013 Q2 | 150.43 Billion IDR | 24.42% |
| 2012 Q3 | 105.03 Billion IDR | 0.0% |
| 2012 FY | 454.94 Billion IDR | -1.76% |
| 2012 Q4 | 116.1 Billion IDR | 10.54% |
| 2011 FY | 463.1 Billion IDR | 2.78% |
| 2010 FY | 450.55 Billion IDR | 8.11% |
| 2009 FY | 416.74 Billion IDR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| PT Merck Tbk | 200.74 Billion IDR | -279.628% |
| PT Phapros, Tbk | 428.44 Billion IDR | -77.87% |
| PT Pyridam Farma Tbk | 293.43 Billion IDR | -159.708% |
| PT Industri Jamu dan Farmasi Sido Muncul Tbk | 827.82 Billion IDR | 7.942% |
| PT Tempo Scan Pacific Tbk | 3255.8 Billion IDR | 76.593% |